Group 1 - Panlong Pharmaceutical (002864.SZ) released its Q3 2025 report on October 28, 2025, indicating that as of October 27, 2025, eight institutional investors disclosed holdings in the company, totaling 4.95 million shares, which represents 4.66% of the total share capital [1] - The institutional investors include various funds and investment management companies, with a total institutional holding percentage increasing by 0.93 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Huatai-PineBridge CSI Traditional Chinese Medicine ETF, increased its holdings by 0.12% compared to the previous period [2] - Two new public funds disclosed their holdings this quarter, including Changxin Jinli Trend Mixed A and Rongtong Health Industry Flexible Allocation Mixed A/B, while 44 public funds were not disclosed compared to the previous quarter [2]

Group 1 - Jilin Aodong (000623.SZ) reported its 2024 annual results on April 23, 2025, with 235 institutional investors holding a total of 414 million shares, representing 34.58% of the total share capital [1] - The top ten institutional investors collectively hold 31.95% of the shares, with a decrease of 6.05 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund increased its holdings, while eight funds decreased their holdings, with a reduction rate of 0.33% [2] - A total of 219 new public funds were disclosed this period, including several major ETFs [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.31% compared to the previous quarter [2]